Monday, 20 November 2017
Latest news
Main » Dynavax Technologies (DVAX) - Cantor Fitzgerald Reiterates Rating

Dynavax Technologies (DVAX) - Cantor Fitzgerald Reiterates Rating

15 November 2017

Candriam Luxembourg S.C.A. decreased its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 53.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The lowest EPS estimate is ($0.35) and the highest is $0.95. During the same period past year, the firm posted ($0.80) EPS. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.53) by $0.15. For the next year, analysts expect that the business will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.26) to ($0.59). GMT Capital Corp boosted its position in shares of Dynavax Technologies Corporation by 28.2% in the second quarter. PointState Capital LP purchased a new stake in shares of Dynavax Technologies Corporation in the second quarter worth about $13,510,000. The company beat the analyst EPS Estimate with the difference of $0.29. At present, 0 analysts call it Sell, while 0 think it is Hold.

Dynavax Technologies Corp. had a negative net margin of 2,068.75% and a negative return on equity of 64.43%. The business's quarterly revenue was up 70.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.90) earnings per share. Recently, analysts have updated the overall rating to 1.8. To measure price-variation, we found DVAX's volatility during a week at 10.6% and during a month it has been found around 7.03%. William Blair reiterated a "buy" rating and set a $45.00 target price on shares of Dynavax Technologies Corp.in a report on Tuesday, September 6th.

Dynavax Technologies Corporation has a beta of 1.57, offering the possibility of a higher rate of return, but also posing more risk.

On November 3 Cowen and Company held the company rating at "Buy" targeting a price of $30.00. Finally, J P Morgan Chase & Co raised Dynavax Technologies Corporation from a "neutral" rating to an "overweight" rating and increased their price target for the company from $6.00 to $27.00 in a report on Monday, July 31st.

HSBC To Pay €300M To Settle French Tax Probe Into Swiss Arm
In a written statement, prosecutors said a Paris court on Tuesday approved the agreement under a 2016 anti-corruption law. HSBC said that under the agreement announced Tuesday, there is no finding of guilt on the part of the Swiss Private Bank.

Cantor Fitzgerald "Maintained" Dynavax Technologies (NASDAQ:DVAX) in a research note issued to investors on 11/10/17 to Overweight with price target of $25. The third largest holder is Gmt Capital Corp, which now holds $61.91 million worth of this stock and that ownership represents almost 5.63% of its market capitalization. If you are accessing this article on another domain, it was stolen and reposted in violation of United States & worldwide trademark and copyright laws. The correct version of this article can be read at https://stocknewstimes.com/2017/11/14/dynavax-technologies-corporation-dvax-expected-to-announce-earnings-of-0-30-per-share.html.

Dynavax Technologies Corporation (NASDAQ:DVAX) tinted gains of +1% (+0.2 points) to US$20.25. California State Teachers Retirement System controls 97,417 shares with a value of $2,094,000.

Dynavax Technologies (NASDAQ:DVAX) 52-week high price stands at $24.45 and low price stands at $3.20, its price distance from 52-week high is -17.18% while its distance from 52-week low price is 532.81%.

A number of institutional investors have recently made changes to their positions in DVAX. LLC bought a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter valued at approximately $7,777,000. The fund owned 89,805 shares of the biopharmaceutical company's stock after acquiring an additional 6,855 shares during the period. Rathbone Brothers plc purchased a new stake in shares of Dynavax Technologies Corp. during the third quarter valued at approximately $105,000. DV230F and DV1001 are in pre-clinical stage of development.